Reliability of Hepatus® for Evaluating Liver Fibrosis in Chronic Hepatitis B
), Muhammad Begawan Bestari(2), Haryono -(3), Dolvy Girawan(4), Nenny Agustanti(5), Yudi Wahyudi(6), Siti Aminah Abdurachman(7),
(1) Division of Gastroenterohepatology, Department of Internal Medicine, University of Padjajaran/Hasan Sadikin Hospital, Bandung
(2) Division of Gastroenterohepatology, Department of Internal Medicine, University of Padjajaran/Hasan Sadikin Hospital, Bandung
(3) Division of Gastroenterohepatology, Department of Internal Medicine, University of Padjajaran/Hasan Sadikin Hospital, Bandung
(4) Division of Gastroenterohepatology, Department of Internal Medicine, University of Padjajaran/Hasan Sadikin Hospital, Bandung
(5) Division of Gastroenterohepatology, Department of Internal Medicine, University of Padjajaran/Hasan Sadikin Hospital, Bandung
(6) Division of Gastroenterohepatology, Department of Internal Medicine, University of Padjajaran/Hasan Sadikin Hospital, Bandung
(7) Division of Gastroenterohepatology, Department of Internal Medicine, University of Padjajaran/Hasan Sadikin Hospital, Bandung
Corresponding Author
Abstract
Abstract
Background
Among non-invasive strategies available for liver fibrosis assessment, transient elastography is widely used, as it is non-invasive and can be repeated. Hepatus® (Mindray, China) is one novel instrument for measuring liver stiffness that is now available in the market with lower price than its precursor, FibroScan® (Echosens, Paris).
Method
In this cross sectional study, CHB patients in single center were recruited consecutively in October 2021-December 2021. The patients were examined for LSM with two transient elastography instruments in one visit. The first instrument was Hepatus® (Mindray, China) and the second one was FibroScan® (Echosens, Paris). Both measurements were done by the same operator.
Results
A total of 68 CHB patients were enrolled in this study. Median score of LSM by Hepatus® and FibroScan® were 7.6 (5.92-11.88) and 7.35 (5.63-11.80) respectively. Spearman rank analysis for correlation showed a significant correlation between the results of the two instruments ( r= 0.8, p <0.05). The number of patients with significant fibrosis (≥8 kPa) identified by Hepatus® and FibroScan® were 28 (41%) and 29 (43%) respectively. McNemar test yielded no significant difference of the results (p= 1.000), and Cohen’s kappa measure of agreement showed moderate agreement (κ = 0.789 and p < 0.005).
Conclusion
Hepatus® identified similar number of significant fibrosis patients with FibroScan®, with the results of liver stiffness measurement between the two instruments correlated significantly. Hepatus® has a potential as an alternative tool for measuring liver stiffness with a more economic price.
Keywords
Hepatus®, FibroScan®, transient elastography, liver fibrosis, CHB
Keywords
References
Reference
Badan Penelitian dan Pengembangan Kesehatan Kementerian RI. Riset Kesehatan Dasar (Riskesdas) 2013. Cited : 20 Februari 2022. Available from https://pusdatin.kemkes.go.id/resources/download/general/Hasil%20Riskesdas%202013.pdf
European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370-398.
Galle PR, Forner A, Llovet JM, et al. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. Journal of Hepatology. 2018;69(1):182-236. doi:10.1016/j.jhep.2018.03.019
Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560-1599. doi:10.1002/hep.29800
Yim HJ, Kim JH, Park JY, et al. Comparison of clinical practice guidelines for the management of chronic hepatitis b: When to start, when to change, and when to stop. Clinical and Molecular Hepatology. 2020;26(4):411-429. doi:10.3350/cmh.2020.0049
Zeng DW, Dong J, Liu YR, Jiang JJ, Zhu YY. Noninvasive models for assessment of liver fibrosis in patients with chronic hepatitis B virus infection. World Journal of Gastroenterology. 2016;22(29):6663-6672. doi:10.3748/wjg.v22.i29.6663
Stasi C, Milani S. Non-invasive assessment of liver fibrosis: Between prediction/prevention of outcomes and cost-effectiveness. World Journal of Gastroenterology. 2016;22(4):1711-1720. doi:10.3748/wjg.v22.i4.1711
Castera L, Yuen Chan HL, Arrese M, et al. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. Journal of Hepatology. 2015;63(1):237-264. doi:10.1016/j.jhep.2015.04.006
Gheorghe G, Bungău S, Ceobanu G, et al. The non-invasive assessment of hepatic fibrosis. Journal of the Formosan Medical Association. 2021;120(2):794-803. doi:10.1016/j.jfma.2020.08.019
Chin JL, Pavlides M, Moolla A, Ryan JD. Non-invasive markers of liver fibrosis: Adjuncts or alternatives to liver biopsy? Frontiers in Pharmacology. 2016;7(JUN). doi:10.3389/fphar.2016.00159
Li Q, Huang C, Xu W, Hu Q, Chen L, Pan. JJ. Accuracy of FibroScan in analysis of liver fibrosis in patients with concomitant chronic Hepatitis B and nonalcoholic fatty liver disease. Medicine (United States). 2020;99(23). doi:10.1097/MD.0000000000020616
FDA. Hepatus 7/Hepatus 6/Hepatus 5/Hepatus 7S/Hepatus 6S/Hepatus 5S/Hepatus 7T/Hepatus 6T/Hepatus 5T/Fibrous 7/Fibrous. Cited 20 February 2022. Available from : https://www.accessdata.fda.gov/scrIpts/cdrh/cfdocs/cfRL/rl.cfm?lid=710282&lpcd=ITX
Lurie Y, Webb M, Cytter-Kuint R, Shteingart S, Lederkremer GZ. Non-invasive diagnosis of liver fibrosis and cirrhosis. World Journal of Gastroenterology. 2015;21(41):11567-11583. doi:10.3748/wjg.v21.i41.11567
Parikh P, Ryan JD, Tsochatzis EA. Fibrosis assessment in patients with chronic hepatitis B virus (HBV) infection. Annals of Translational Medicine. 2017;5(3). doi:10.21037/atm.2017.01.28
Chon YE, Choi EH, Song KJ, et al. Performance of Transient Elastography for the Staging of Liver Fibrosis in Patients with Chronic Hepatitis B: A Meta-Analysis. PLoS ONE. 2012;7(9). doi:10.1371/journal.pone.0044930
WHO. Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection. Geneva: World Health Organization; March 2015.
Yu JH, Lee J il. Current role of transient elastography in the management of chronic hepatitis B patients. Ultrasonography. 2017;36(2):86-94. doi:10.14366/usg.16023
Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatology International. 2016;10(1):1-98. doi:10.1007/s12072-015-9675-4
Patel K, Sebastiani G. Limitations of Non-Invasive Tests for Assessment of Liver Fibrosis.; 2020.
Ren X, Xia S, Zhang L, et al. Analysis of liver steatosis analysis and controlled attenuation parameter for grading liver steatosis in patients with chronic hepatitis B. Quantitative Imaging in Medicine and Surgery. 2021;11(2):571-578. doi:10.21037/QIMS-19-1091
Berger A, Shili S, Zuberbuhler F, et al. Liver stiffness measurement with fibroscan: Use the right probe in the right conditions! Clinical and Translational Gastroenterology. 2019;10(4). doi:10.14309/ctg.0000000000000023
Myers RP, Pomier-Layrargues G, Kirsch R, et al. Discordance in fibrosis staging between liver biopsy and transient elastography using the FibroScan XL probe. Journal of Hepatology. 2012;56(3):564-570. doi:10.1016/j.jhep.2011.10.007
Chang PE. Clinical applications, limitations and future role of transient elastography in the management of liver disease. World Journal of Gastrointestinal Pharmacology and Therapeutics. 2016;7(1):91. doi:10.4292/wjgpt.v7.i1.91
Article Metrics
Abstract View
: 2599 times
Download : 1336 times
DOI: 10.24871/2322022112-116
Refbacks
- There are currently no refbacks.
